HIV: Current Research
Open Access
ISSN: 2572-0805
+44 1300 500008
ISSN: 2572-0805
+44 1300 500008
Loss of CD4+ T cells signifies the immunological compromise brought on by the human immunodeficiency virus (HIV). As the quantity of these cells in peripheral blood (CD4+ count) decreases, the rates of HIV-related illnesses and fatalities rise. Antiretroviral medication is typically started later in asymptomatic patients with a CD4+ count over a predetermined threshold. The relevant threshold has evolved over time, and various guidelines continue to make varying suggestions. Patients with a CD4+ count of less than 500 cells per cubic millimetre have been enrolled in the majority of random studies that have evaluated the advantages and disadvantages. A CD4+ count of 200 or 250 cells per cubic millimetre has been used as the definition of "later" in several studies. Strong support for the start of antiretroviral medication in patients with a CD4+ count of 350 cells per cubic millimetre is shown by these results and observational studies
Published Date: 2022-12-12; Received Date: 2022-11-08